GGrantIndex
Sort

39,280 grants matching leukemia

Targeted aberrant signaling in CBL-mutant leukemia

$388,111
Benjamin Levine Ebert · Dana-Farber Cancer Inst · P01 · FY2021 · CA

A Rapid and Comprehensive Approach for Clinical Genomic Profiling in Lung Cancer

$388,026
Eric J Duncavage · Washington University · R33 · FY2023 · CA

PD-L1 interacts with CD80 and PD-1 to regulate GVHD and GVL activity

$388,013
Defu Zeng · Beckman Research Institute/City Of Hope · R01 · FY2022 · CA

Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL

$388,003
Tomasz Skorski · Temple Univ Of The Commonwealth · R01 · FY2022 · CA

Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL

$387,997
Tomasz Skorski · Temple Univ Of The Commonwealth · R01 · FY2021 · CA

New Theraputics for Graft-Versus-Host Disease

$387,982
Krishna Kumar · Chemokine Pharmaceutical, Inc. · R43 · FY2006 · AI

New Theraputics for Graft-Versus-Host Disease

$387,982
Mi Youn Lim · Chemokine Pharmaceutical, Inc. · R43 · FY2007 · AI

Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma

$387,981
Jose R Conejo-Garcia · Duke University · R01 · FY2023 · CA

Molecular Basis of Drosophila Homeotic Gene Regulation

$387,936
Case Western Reserve University · R01 · FY2004 · GM

Regulation of GLI1, a synthetic lethal target of SMARCA4-deficiency, in lung adenocarcinoma

$387,868
James Kim · Ut Southwestern Medical Center · R01 · FY2025 · CA

Explore the signaling mechanisms of acquired resistance to tyrosine kinase inhibitors in AML

$387,863
Jian Huang · Coriell Institute For Medical Research · R01 · FY2024 · CA

Growth factors and engineered stroma for hematopoietic stem csll (HSC) expansion

$387,837
Harvey F Lodish · Whitehead Institute For Biomedical Res · R01 · FY2010 · DK

Arsenic-induced apoptosis in myeloma

$387,826
Lawrence H Boise · Emory University · R01 · FY2010 · CA

Role of BAZ2A in MLL-r leukemia and therapeutic response

$387,823
Chun-Wei David Chen · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA

Combinational targeting the feed forward epigenetic circuitry in mixed lineage leukemia

$387,823
Chun-Wei David Chen · Beckman Research Institute/City Of Hope · R37 · FY2023 · CA

Role of Abl Kinases in immune cell signaling

$387,789
Ann Marie Pendergast · Duke University · R01 · FY2014 · AI

Role of Abl Kinases in immune cell signaling

$387,789
Ann Marie Pendergast · Duke University · R01 · FY2015 · AI

Role of Abl Kinases in immune cell signaling

$387,789
Ann Marie Pendergast · Duke University · R01 · FY2012 · AI

Validating Syk as a Target for AML Therapy

$387,775
Kimberly Stegmaier · Dana-Farber Cancer Inst · R01 · FY2014 · CA

E2A AS A POTENTIAL TUMOR SUPPRESSOR

$387,731
University Of California San Diego · R01 · FY2002 · CA

Function and targeting of a stable transcription factor complex in leukemia

$387,731
Robert G Roeder · Rockefeller University · R01 · FY2021 · CA

Function and targeting of a stable transcription factor complex in leukemia

$387,731
Robert G Roeder · Rockefeller University · R01 · FY2020 · CA

Validating Syk as a Target for AML Therapy

$387,731
Kimberly Stegmaier · Dana-Farber Cancer Inst · R01 · FY2015 · CA

Altered Communication between the nucleus and the mitochondria under oncogenic states

$387,731
Michael P Rout · Rockefeller University · R01 · FY2021 · CA

Transcriptional Mechanism of BRD4 in Solid Tumor

$387,731
Ming-Ming Zhou · Icahn School Of Medicine At Mount Sinai · R01 · FY2019 · CA